BoneSupport

13 Sep CERAMENT G showing outstanding long-term results

Posted at 10:32h in News by
0 Likes

BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces the publication of mid- to long-term data confirming the sustained clinical effectiveness of CERAMENT G in a single-stage protocol to manage chronic osteomyelitis.

The study followed 100 patients treated at the Nuffield Orthopaedic Centre, Oxford University Hospitals. Results at a mean follow-up of 6.05 years [range: 4.2 to 8.4 years] were reported:

  • 94% of patients remained infection-free
  • 3% fracture rate and no further pathologic fractures beyond the first year after surgery

“These results over a long follow-up period confirm that our protocol using CERAMENT G remains highly effective over several years. There are hardly any prospective studies on bone graft substitutes with a follow-up over two years. Additionally, we were able to achieve these results in single-stage operation due to CERAMENT G’s unique properties of eluting high concentrations of local antibiotics and providing bone remodeling. Reducing the number of surgical procedures is more patient-friendly and allows for a cost-effective strategy to tackle chronic osteomyelitis,” said Professor Martin McNally, lead author and lead consultant in limb reconstruction surgery at Oxford University Hospital.

The study was published in the September issue of The Bone and Joint Journal (see reference below). The long-term results will be presented, and has been selected as one of the ten best papers, at this year’s annual meeting of the European Bone and Joint Infection Society (EBJIS) held in Graz, Austria on 8-10 September. Approximately 500 surgeons are expected to attend.

“Professor McNally’s group show long-term results that have not been displayed with any other orthobiologics product. This study will be influential in transforming the standard of care,” said Emil Billbäck, CEO of BONESUPPORT.

CERAMENT G is implanted to promote bone healing in bone voids or defects and simultaneously to protect it from infection. More than 70,000 patients have been treated thus far using the CERAMENT bone healing technology.

Reference

McNally, M, et al., ‘Mid- to Long-Term Results of Single-Stage Surgery for Patients with Chronic Osteomyelitis Using a Bioabsorbable Gentamicin-Loaded Ceramic Carrier’, The Bone & Joint Journal, 104-B.9 (2022), 1095–1100 <https://doi.org/10.1302/0301-620X.104B9.BJJ-2022-0396.R1>

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

CERAMENT®G showing outstanding long-term results

SOURCE: BoneSupport, September 8, 2022.

To find out more news from the industry head over to our news section – orthocg.com/news